Which specific practice or approach has most accelerated your biotech or drug discovery work with AI, and why?

The answers highlight AI's impact on molecular design, early-stage prediction, and experiment structuring, with each emphasizing a different stage or approach in accelerating drug discovery.

5 answers

Answers

  • Harry Stebbings

    Founder · 20vc

    Drugging the Undruggable

    Harry Stebbings says using AI to drug the undruggable is by far the greatest potential and impact he expects from the technology, citing the coming pace of discovery in biology and drug development.

    20VC with Harry Stebbings · Watch on YouTube
  • Joshua Weiner

    Senior Vice President Consumer Engagement & Analytics · Cvs Health

    Molecular Generation

    Joshua Weiner says his company CHAI has started on the molecular generation process, which he describes as the apex for the other things that can happen around it.

    The answer starts at 20:48.

    Stanford Online: University Courses & Lectures · Listen on Apple Podcasts
  • Simeon George

    Chief Executive Officer and Co-Founder · Sr One Capital Management

    Early Development Focus

    Simeon George says his firm's thesis is to focus on early development, using AI to predict late-stage outcomes from early decisions and to learn from early molecule reps, because early studies are smaller, shorter and cheaper, giving the most impact before costly late-stage trials.

    Life Science Connect · Watch on YouTube
  • Sylke Poehling, PhD

    SVP and Global Head: Therapeutic Modalities, pRED; Roche Gene Therapy Center of Excellence · Roche

    Large Variant Libraries

    Sylke Poehling says AI's clearest value is in design, where large variant libraries can be built and tested in parallel so a model can learn which sequences have the needed properties, because experiments close to a sequence can be run at scale.

    Life Science Connect · Watch on YouTube
  • Fiona H. Marshall

    President, Biomedical Research · Novartis

    Data Scientists Lead Experiments

    Fiona H. Marshall says she has turned the old setup upside down so that data scientists now design the experiments, making them fit for AI analysis and enablement.

    Vanguards of Healthcare by Bloomberg Intelligence · Vanguards of Healthcare by Bloomberg Intelligence · Listen at 45:24

More Biotechnology questions

View all →